Blood levels alone cannot confirm safe testosterone dosing. Asking about androgenic effects and allowing months for response are central to care.
|Videos|October 2, 2022
Considerations for perimenopausal contraception
Author(s)Lindsey Carr, Editor
Lois McGuire, MSN, APRN, WHNP-BC, NCMP, shared her expertise in perimenopausal contraception during the Nurse Practitioners in Women’s Health (NPWH) 25th Annual Premier Women’s Health Conference, held in Houston, Texas from September 28 to October 2, 2022.
Advertisement
Contemporary OB/GYN® caught up with McGuire after her presentation to take a deeper dive into the topic.
Catch up on our coverage of
Advertisement
Related to this article
A global consensus defines what the evidence supports for testosterone in women. Benefits for strength, mood, and cognition lack randomized data.
A testosterone patch improved sexual desire in trials but never won US approval. Normal female physiology defines what replacement should target.
The WHI never studied testosterone, yet it chilled conversations about every hormone, with lasting consequences for women’s sexual health.
As estrogen came to define menopause care, testosterone faded from view, and the oral combination clinicians relied on was never FDA approved.
Androgen therapy for women predates the headlines by decades. Early research showed promise for desire, but long-term safety data never caught up.
Patients with 3 or more adverse pregnancy outcomes had lower odds of postpartum contraceptive use in a PRAMS analysis of 222,412 individuals.
Mental health, bias, and trauma shape sexual health visits, and histories should assess function, not just risk, according to Sameena Rahman, MD.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
What biomarker-guided preeclampsia care could look like
2
Testosterone for women: Global consensus and physiologic dosing
3
Testosterone physiology in women and the long road to approval
4
Testosterone in women: Androgenic adverse events and lab monitoring
5